ข่าวประชาสัมพันธ์ Lung Cancer+vandetanib

NCC Spreads Hope for Breast Cancer Patients Donates Proceeds from '12th August Half Marathon 2024' to the Thai Red Cross Society

N.C.C. Management and Development Co., Ltd., the operator of Queen Sirikit National Convention Center, represented by Mr. Surapol Utintu (2nd left), Managing Director, has donated all proceeds after expense deduction of 500,000 Baht from the "12th August Bangkok Half Marathon 2024" to Mr. Khan Prachyabmoh (3rd left), Director of the Fundraising Bureau, Thai Red Cross Society. The donation will support the Queen Sirikit Centre for Breast Cancer (QSCBC) based at King Chulalongkorn Memorial

CAPRELSA(TM) (vandetanib) Receives Positive CHMP Opinion in the European Union for Treating Advanced Medullary Thyroid Cancer

AstraZeneca today announced that the Marketing Authorisation Application for CAPRELSA (vandetanib) received a positive opinion from the Committee for Medicinal Products for...

Vandetanib Phase II Trial Shows Significant Improvement of Progression Free Survival in Patients With Advanced Papillary or Follicular Thyroid Cancer

- This press release has been made available on worldwide (excluding US) press communication media for the benefit of correspondents writing for the...

Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology

Data from the Phase III ZODIAC(1) study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, were...

Fourth Phase III Study of Vandetanib (ZACTIMA(TM), ZD6474) in Patients With Advanced Lung Cancer

A Phase III international, parallel group, randomised, double-blind study of vandetanib in combination with pemetrexed for advanced non-small cell lung cancer (NSCLC) after failure of first line anti...